CEL-SCI

CVMPhase 3

Founded 1983cel-sci.com

CEL-SCI is a publicly traded biotech company (NYSE American: CVM) founded in 1983, dedicated to developing immune-based therapies for cancer, autoimmune, and infectious diseases. Its core strategy involves activating the immune system at the point of diagnosis, before the immune system is compromised by conventional treatments. The company's landmark global Phase 3 trial in head and neck cancer, one of the largest ever in the indication, demonstrated a 14.1% absolute overall survival advantage at five years, positioning Multikine for a potential regulatory filing and a new treatment paradigm in oncology.

Market Cap

$29.1M

Founded

1983

Focus

Biologics

AI Company Overview

Technology Platform

CEL-SCI's core platform is neoadjuvant immunotherapy, administering immune-stimulating therapies before standard cancer treatments. Its LEAPS (Ligand Epitope Antigen Presentation System) technology is a separate early-stage platform for modulating immune responses in autoimmune and infectious diseases.

Pipeline Snapshot

3 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
LI + Cyclophosphamide + Indomethacin + Cisplatin	Squamous Cell Carcinoma of the Oral Cavity	Phase 3
Leukocyte Interleukin, Injection 200IU + Leukocyte Interleukin, injection 400IU	Condyloma	Phase 1
Leukocyte Interleukin, Injection	Perianal Warts	Phase 1

Opportunities

The primary growth opportunity is the global commercialization of Multikine for approximately 210,000 annual head and neck cancer cases, representing a multi-billion dollar market.

Success could establish a new neoadjuvant immunotherapy paradigm applicable to other solid tumors.

The LEAPS platform offers long-term optionality in autoimmune and infectious disease markets.

Risk Factors

Key risks include regulatory rejection or delays for Multikine's BLA, the need for substantial additional capital to fund submission and commercialization, and challenges in competing commercially as a small company in the oncology market.

The Phase 3 data showed benefit only in the patient subset not receiving chemotherapy.

Competitive Landscape

Main competitors are checkpoint inhibitors (Keytruda, Opdivo) used in later-line head and neck cancer. CEL-SCI's key differentiation is its neoadjuvant use in newly diagnosed patients. It faces competition from other companies exploring neoadjuvant immuno-oncology approaches but has a first-mover advantage with Phase 3 data in this specific setting.